Back to search results

Carboplatin, Paclitaxel, and Ramucirumab for NSCLC

This study is looking at a combination of three anti-cancer drugs: carboplatin, paclitaxel, and ramucirumab. Researchers want to see if these drugs can shrink tumors or slow their growth in people with non-small cell lung cancer (NSCLC). They will also check if this combination is safe. You might be able to join if you are an adult with advanced non-squamous NSCLC that has progressed after previous treatment with Pemetrexed, Pembrolizumab, or both. The main goal is to see how many people respond to the treatment over three years. The current status of this study is unclear, and it plans to enroll about 59 participants.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 59 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure how many people respond to the treatment at 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04332367

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Recruiting
PHASE2Ages 18+InterventionalTreatment
Abramson Cancer Center at Penn Medicine
~59 participants
Updated 2026-06-10 on ClinicalTrials.gov
What's tested:CarboplatinPaclitaxelRamucirumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To estimate overall response rate
Measured over 3 years

Conditions

Non-small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Melina Marmarelis, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center at Penn Medicine

Who to contact

Melissa Volpe, BA
[email protected]
215-220-9703
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
PS 0-1

Exclusion

Presence of a driver mutation that is susceptible to targeted therapy
Other active invasive malignancy requiring ongoing therapy
Grade 2 or higher sensory neuropathy
Evidence of untreated brain metastases
History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)

What this trial measures

  • To estimate overall response rate3 years

    Overall response rate (ORR) as determined by RECIST criteria. Response will be defined by a complete response (CR) or partial response (PRO), confirmed or unconfirmed.